Bahl & Gaynor’s CME Group CME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$138M Sell
623,642
-7,080
-1% -$1.96M 0.64% 55
2026
Q1
$186M Buy
630,722
+2,715
+0.4% +$806K 0.94% 32
2025
Q4
$171M Buy
628,007
+31,104
+5% +$8.45M 0.87% 36
2025
Q3
$161M Sell
596,903
-22,570
-4% -$6.14M 0.8% 39
2025
Q2
$171M Sell
619,473
-11,067
-2% -$3.01M 0.86% 32
2025
Q1
$167M Buy
630,540
+15,912
+3% +$3.93M 0.85% 35
2024
Q4
$143M Buy
614,628
+57,439
+10% +$13.2M 0.75% 39
2024
Q3
$123M Buy
557,189
+14,159
+3% +$2.93M 0.63% 46
2024
Q2
$107M Buy
543,030
+46,714
+9% +$9.65M 0.6% 50
2024
Q1
$107M Buy
496,316
+357,286
+257% +$75.1M 0.59% 51
2023
Q4
$29.3M Buy
+139,030
New +$29.7M 0.18% 83
2020
Q3
– Sell
-2,479
Closed -$403K – 333
2020
Q2
$403K Sell
2,479
-3,845
-61% -$689K ﹤0.01% 295
2020
Q1
$1.09M Sell
6,324
-25
-0.4% -$4.98K 0.01% 249
2019
Q4
$1.27M Sell
6,349
-1,715
-21% -$352K 0.01% 265
2019
Q3
$1.7M Buy
8,064
+161
+2% +$33.6K 0.01% 240
2019
Q2
$1.53M Buy
+7,903
New +$1.46M 0.01% 249

Other funds holding CME

Bahl & Gaynor's CME Position: Q2 2026 in Review

Bahl & Gaynor reduced its CME Group (CME) stake by 1.1% in Q2 2026, selling an estimated $1.96M and leaving 623,642 shares worth $138M. The position accounts for 0.64% of the portfolio, ranked #55.

Bahl & Gaynor first reported a position in CME in Q2 2019 and has held it in 16 quarters since. The position peaked at $186M in Q1 2026. 1,710 funds tracked by Wall St. Rank hold CME as of Q2 2026.

  • Bahl & Gaynor held 623,642 shares of CME Group worth $138M as of Q2 2026.
  • Bahl & Gaynor sold 7,080 CME Group shares in Q2 2026, an estimated $1.96M.
  • CME Group made up 0.64% of Bahl & Gaynor's portfolio in Q2 2026, its #55 holding.
  • Bahl & Gaynor first reported a position in CME Group in Q2 2019 and has held it in 16 quarters since.
  • Bahl & Gaynor's CME Group position peaked at $186M in Q1 2026.
  • 1,710 funds tracked by Wall St. Rank held CME Group as of Q2 2026.

Based on Bahl & Gaynor's 13F filing for Q2 2026, filed 13 Aug 2026.